Login Register Cart 0
Generic placeholder image

Current Neuropharmacology

Editor-in-Chief

ISSN (Print): 1570-159X
ISSN (Online): 1875-6190

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
General Review Article

Advances in the Pharmacological and Non-pharmacological Management of Non-motor Symptoms in Parkinson’s Disease: An Update Since 2017

Author(s): Daniel J. Van Wamelen*, Katarina Rukavina, Aleksandra M. Podlewska and K. Ray Chaudhuri

Volume 21, Issue 8, 2023

Published on: 08 June, 2022

Page: [1786 - 1805] Pages: 20

DOI: 10.2174/1570159X20666220315163856

Price: $65

conference banner
Abstract

Background: Non-motor symptoms (NMS) are an important and ubiquitous determinant of quality of life in Parkinson’s disease (PD). However, robust evidence for their treatment is still a major unmet need.

Objective: This study aimed to provide an updated review on advances in pharmacological, nonpharmacological, and exercise-based interventions for NMS in PD, covering the period since the publication of the MDS Task Force Recommendations.

Methods: We performed a literature search to identify pharmacological, non-pharmacological, and exercise-based interventions for NMS in PD. As there are recent reviews on the subject, we have only included studies from the 1st of January 2017 to the 1st of December 2021 and limited our search to randomised and non-randomised (including open-label) clinical trials.

Results: We discuss new strategies to manage NMS based on data that have become available since 2017, for instance, on the treatment of orthostatic hypotension with droxidopa, several dopaminergic treatment options for insomnia, and a range of non-pharmacological and exercise-based interventions for cognitive and neuropsychiatric symptoms, pain, and insomnia and excessive sleepiness.

Conclusion: Recent evidence suggests that targeted non-pharmacological treatments, as well as some other NMS management options, may have a significant beneficial effect on the quality of life and need to be considered in the pathways of treatment of PD.

Keywords: Parkinson's disease, non-motor symptoms, autonomic symptoms, neuropsychiatric symptoms, pain, treatment, nonpharmacological treatment.

« Previous Next »
[1]
van Wamelen, D.J.; Sauerbier, A.; Leta, V.; Rodriguez-Blazquez, C.; Falup-Pecurariu, C.; Rodriguez-Violante, M.; Rizos, A.; Tsuboi, Y.; Metta, V.; Bhidayasiri, R.; Bhattacharya, K.; Borgohain, R.; Prashanth, L.K.; Rosales, R.; Lewis, S.; Fung, V.; Behari, M.; Goyal, V.; Kishore, A.; Lloret, S.P.; Martinez-Martin, P.; Chaudhuri, K.R. Cross-sectional analysis of the Parkinson’s disease Non-motor International Longitudinal Study baseline non-motor characteristics, geographical distribution and impact on quality of life. Sci. Rep., 2021, 11(1), 9611.
[http://dx.doi.org/10.1038/s41598-021-88651-4] [PMID: 33953218]
[2]
Parkinson, J. An essay on the shaking palsy. 1817. J. Neuropsychiatry Clin. Neurosci., 2002, 14(2), 223-236.
[http://dx.doi.org/10.1176/jnp.14.2.223] [PMID: 11983801]
[3]
Titova, N.; Chaudhuri, K.R. Non-motor Parkinson disease: new concepts and personalised management. Med. J. Aust., 2018, 208(9), 404-409.
[http://dx.doi.org/10.5694/mja17.00993] [PMID: 29764353]
[4]
Zis, P.; Martinez-Martin, P.; Sauerbier, A.; Rizos, A.; Sharma, J.C.; Worth, P.F.; Sophia, R.; Silverdale, M.; Chaudhuri, K.R. Non-motor symptoms burden in treated and untreated early Parkinson’s disease patients: argument for non-motor subtypes. Eur. J. Neurol., 2015, 22(8), 1145-1150.
[http://dx.doi.org/10.1111/ene.12733] [PMID: 25981492]
[5]
Seppi, K.; Ray, C.K.; Coelho, M.; Fox, S.H.; Katzenschlager, R.; Perez Lloret, S.; Weintraub, D.; Sampaio, C. Update on treatments for nonmotor symptoms of Parkinson’s disease-an evidence-based medicine review. Mov. Disord., 2019, 34(2), 180-198.
[http://dx.doi.org/10.1002/mds.27602] [PMID: 30653247]
[6]
Marras, C.; Chaudhuri, K.R.; Titova, N.; Mestre, T.A. Therapy of Parkinson’s disease subtypes. Neurotherapeutics, 2020, 17(4), 1366-1377.
[http://dx.doi.org/10.1007/s13311-020-00894-7] [PMID: 32749651]
[7]
Titova, N.; Qamar, M.A.; Chaudhuri, K.R. The nonmotor features of Parkinson’s disease. Int. Rev. Neurobiol., 2017, 132, 33-54.
[http://dx.doi.org/10.1016/bs.irn.2017.02.016] [PMID: 28554413]
[8]
Rukavina, K.; Batzu, L.; Boogers, A.; Abundes-Corona, A.; Bruno, V.; Chaudhuri, K.R. Non-motor complications in late stage Parkinson’s disease: recognition, management and unmet needs. Expert Rev. Neurother., 2021, 21(3), 335-352.
[http://dx.doi.org/10.1080/14737175.2021.1883428] [PMID: 33522312]
[9]
van Wamelen, D.J.; Martinez-Martin, P.; Weintraub, D.; Schrag, A.; Antonini, A.; Falup-Pecurariu, C.; Odin, P.; Ray Chaudhuri, K. The non-motor symptoms scale in Parkinson’s disease: Validation and use. Acta Neurol. Scand., 2021, 143(1), 3-12.
[http://dx.doi.org/10.1111/ane.13336] [PMID: 32813911]
[10]
Burns, P.B.; Rohrich, R.J.; Chung, K.C. The levels of evidence and their role in evidence-based medicine. Plast. Reconstr. Surg., 2011, 128(1), 305-310.
[http://dx.doi.org/10.1097/PRS.0b013e318219c171] [PMID: 21701348]
[11]
Cilia, R.; Laguna, J.; Cassani, E.; Cereda, E.; Raspini, B.; Barichella, M.; Pezzoli, G. Daily intake of Mucuna pruriens in advanced Parkinson’s disease: A 16-week, noninferiority, randomized, crossover, pilot study. Parkinsonism Relat. Disord., 2018, 49, 60-66.
[http://dx.doi.org/10.1016/j.parkreldis.2018.01.014] [PMID: 29352722]
[12]
Peball, M.; Krismer, F.; Knaus, H.G.; Djamshidian, A.; Werkmann, M.; Carbone, F.; Ellmerer, P.; Heim, B.; Marini, K.; Valent, D.; Goebel, G.; Ulmer, H.; Stockner, H.; Wenning, G.K.; Stolz, R.; Krejcy, K.; Poewe, W.; Seppi, K. Non-motor symptoms in Parkinson’s Disease are reduced by nabilone. Ann. Neurol., 2020, 88(4), 712-722.
[http://dx.doi.org/10.1002/ana.25864] [PMID: 32757413]
[13]
Wilkinson, D.; Podlewska, A.; Banducci, S.E.; Pellat-Higgins, T.; Slade, M.; Bodani, M.; Sakel, M.; Smith, L.; LeWitt, P.; Ade, K.K. Caloric vestibular stimulation for the management of motor and non-motor symptoms in Parkinson’s disease. Parkinsonism Relat. Disord., 2019, 65, 261-266.
[http://dx.doi.org/10.1016/j.parkreldis.2019.05.031] [PMID: 31300264]
[14]
Müller, T.; Öhm, G.; Eilert, K.; Möhr, K.; Rotter, S.; Haas, T.; Küchler, M.; Lütge, S.; Marg, M.; Rothe, H. Benefit on motor and non-motor behavior in a specialized unit for Parkinson’s disease. J. Neural Transm. (Vienna), 2017, 124(6), 715-720.
[http://dx.doi.org/10.1007/s00702-017-1701-3] [PMID: 28247031]
[15]
Mullin, S.; Smith, L.; Lee, K.; D’Souza, G.; Woodgate, P.; Elflein, J.; Hällqvist, J.; Toffoli, M.; Streeter, A.; Hosking, J.; Heywood, W.E.; Khengar, R.; Campbell, P.; Hehir, J.; Cable, S.; Mills, K.; Zetterberg, H.; Limousin, P.; Libri, V.; Foltynie, T.; Schapira, A.H.V. Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations: a nonrandomized, noncontrolled trial. JAMA Neurol., 2020, 77(4), 427-434.
[http://dx.doi.org/10.1001/jamaneurol.2019.4611] [PMID: 31930374]
[16]
van Horne, C.G.; Quintero, J.E.; Slevin, J.T.; Anderson-Mooney, A.; Gurwell, J.A.; Welleford, A.S.; Lamm, J.R.; Wagner, R.P.; Gerhardt, G.A. Peripheral nerve grafts implanted into the substantia nigra in patients with Parkinson’s disease during deep brain stimulation surgery: 1-year follow-up study of safety, feasibility, and clinical outcome. J. Neurosurg., 2018, 129(6), 1550-1561.
[http://dx.doi.org/10.3171/2017.8.JNS163222] [PMID: 29451447]
[17]
Whone, A.; Luz, M.; Boca, M.; Woolley, M.; Mooney, L.; Dharia, S.; Broadfoot, J.; Cronin, D.; Schroers, C.; Barua, N.U.; Longpre, L.; Barclay, C.L.; Boiko, C.; Johnson, G.A.; Fibiger, H.C.; Harrison, R.; Lewis, O.; Pritchard, G.; Howell, M.; Irving, C.; Johnson, D.; Kinch, S.; Marshall, C.; Lawrence, A.D.; Blinder, S.; Sossi, V.; Stoessl, A.J.; Skinner, P.; Mohr, E.; Gill, S.S. Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson’s disease. Brain, 2019, 142(3), 512-525.
[http://dx.doi.org/10.1093/brain/awz023] [PMID: 30808022]
[18]
Bouhaddi, M.; Vuillier, F.; Fortrat, J.O.; Cappelle, S.; Henriet, M.T.; Rumbach, L.; Regnard, J. Impaired cardiovascular autonomic control in newly and long-term-treated patients with Parkinson’s disease: involvement of L-dopa therapy. Auton. Neurosci., 2004, 116(1-2), 30-38.
[http://dx.doi.org/10.1016/j.autneu.2004.06.009] [PMID: 15556835]
[19]
Postuma, R.B.; Gagnon, J.F.; Pelletier, A.; Montplaisir, J. Prodromal autonomic symptoms and signs in Parkinson’s disease and dementia with Lewy bodies. Mov. Disord., 2013, 28(5), 597-604.
[http://dx.doi.org/10.1002/mds.25445] [PMID: 23554107]
[20]
Adams-Carr, K.L.; Bestwick, J.P.; Shribman, S.; Lees, A.; Schrag, A.; Noyce, A.J. Constipation preceding Parkinson’s disease: a systematic review and meta-analysis. J. Neurol. Neurosurg. Psychiatry, 2016, 87(7), 710-716.
[http://dx.doi.org/10.1136/jnnp-2015-311680] [PMID: 26345189]
[21]
Biaggioni, I.; Arthur Hewitt, L.; Rowse, G.J.; Kaufmann, H. Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension. BMC Neurol., 2017, 17(1), 90.
[http://dx.doi.org/10.1186/s12883-017-0867-5] [PMID: 28494751]
[22]
Schreglmann, S.R.; Büchele, F.; Sommerauer, M.; Epprecht, L.; Kägi, G.; Hägele-Link, S.; Götze, O.; Zimmerli, L.; Waldvogel, D.; Baumann, C.R. Pyridostigmine bromide versus fludrocortisone in the treatment of orthostatic hypotension in Parkinson’s disease - a randomized controlled trial. Eur. J. Neurol., 2017, 24(4), 545-551.
[http://dx.doi.org/10.1111/ene.13260] [PMID: 28224720]
[23]
Kanegusuku, H.; Silva-Batista, C.; Peçanha, T.; Nieuwboer, A.; Silva, N.D., Jr; Costa, L.A.; de Mello, M.T.; Piemonte, M.E.; Ugrinowitsch, C.; Forjaz, C.L. Effects of progressive resistance training on cardiovascular autonomic regulation in patients with parkinson disease: A randomized controlled trial. Arch. Phys. Med. Rehabil., 2017, 98(11), 2134-2141.
[http://dx.doi.org/10.1016/j.apmr.2017.06.009] [PMID: 28705551]
[24]
Erro, R.; Picillo, M.; Vitale, C.; Amboni, M.; Moccia, M.; Santangelo, G.; Pellecchia, M.T.; Barone, P. The non-motor side of the honeymoon period of Parkinson’s disease and its relationship with quality of life: a 4-year longitudinal study. Eur. J. Neurol., 2016, 23(11), 1673-1679.
[http://dx.doi.org/10.1111/ene.13106] [PMID: 27435448]
[25]
Giorelli, M.; Bagnoli, J.; Consiglio, L.; Difazio, P.; Zizza, D.; Zimatore, G.B. Change in non-motor symptoms in Parkinson’s disease and essential tremor patients: A one-year follow-up study. Tremor Other Hyperkinet. Mov. (N. Y.), 2014, 4, 216.
[http://dx.doi.org/10.5334/tohm.189] [PMID: 24757583]
[26]
van Wamelen, D.J.; Leta, V.; Johnson, J.; Ocampo, C.L.; Podlewska, A.M.; Rukavina, K.; Rizos, A.; Martinez-Martin, P.; Chaudhuri, K.R. Drooling in Parkinson’s disease: Prevalence and progression from the non-motor international longitudinal study. Dysphagia, 2020, 35(6), 955-961.
[http://dx.doi.org/10.1007/s00455-020-10102-5] [PMID: 32130515]
[27]
Tiigimäe-Saar, J.; Tamme, T.; Rosenthal, M.; Kadastik-Eerme, L.; Taba, P. Saliva changes in Parkinson’s disease patients after injection of Botulinum neurotoxin type A. Neurol. Sci., 2018, 39(5), 871-877.
[http://dx.doi.org/10.1007/s10072-018-3279-4] [PMID: 29460161]
[28]
Isaacson, S.H.; Ondo, W.; Jackson, C.E.; Trosch, R.M.; Molho, E.; Pagan, F.; Lew, M.; Dashtipour, K.; Clinch, T.; Espay, A.J. Safety and efficacy of rimabotulinumtoxinB for treatment of sialorrhea in adults: A randomized clinical trial. JAMA Neurol., 2020, 77(4), 461-469.
[http://dx.doi.org/10.1001/jamaneurol.2019.4565] [PMID: 31930364]
[29]
Jost, W.H.; Friedman, A.; Michel, O.; Oehlwein, C.; Slawek, J.; Bogucki, A.; Ochudlo, S.; Banach, M.; Pagan, F.; Flatau-Baqué, B.; Csikós, J.; Cairney, C.J.; Blitzer, A. SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea. Neurology, 2019, 92(17), e1982-e1991.
[http://dx.doi.org/10.1212/WNL.0000000000007368] [PMID: 30918101]
[30]
Cheng, Y.Q.; Ge, N.N.; Zhu, H.H.; Sha, Z.T.; Jiang, T.; Zhang, Y.D.; Tian, Y.Y. Dihydroergotoxine mesylate for the treatment of sialorrhea in Parkinson’s disease. Parkinsonism Relat. Disord., 2019, 58, 70-73.
[http://dx.doi.org/10.1016/j.parkreldis.2018.08.022] [PMID: 30177490]
[31]
Stocchi, F.; Torti, M. Constipation in Parkinson’s Disease. Int. Rev. Neurobiol., 2017, 134, 811-826.
[http://dx.doi.org/10.1016/bs.irn.2017.06.003] [PMID: 28805584]
[32]
Tan, A.H.; Lim, S-Y.; Chong, K.K.; Manap, A. M.A.A.; Hor, J.W.; Lim, J.L.; Low, S.C.; Chong, C.W.; Mahadeva, S.; Lang, A.E. Probiotics for constipation in Parkinson’s disease: A randomized placebo-controlled study. Neurology, 2021, 96(5), e772-e782.
[PMID: 33046607]
[33]
Reichmann, H.; Lees, A.; Rocha, J.F.; Magalhães, D.; Soares-da-Silva, P. Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study. Transl. Neurodegener., 2020, 9(1), 9.
[http://dx.doi.org/10.1186/s40035-020-00187-1] [PMID: 32345378]
[34]
Quarracino, C.; Otero-Losada, M.; Capani, F.; Pérez-Lloret, S. State-of-the-art pharmacotherapy for autonomic dysfunction in Parkinson’s disease. Expert Opin. Pharmacother., 2020, 21(4), 445-457.
[http://dx.doi.org/10.1080/14656566.2020.1713097] [PMID: 31957505]
[35]
Niemann, N.; Billnitzer, A.; Jankovic, J. Parkinson’s disease and skin. Parkinsonism Relat. Disord., 2021, 82, 61-76.
[http://dx.doi.org/10.1016/j.parkreldis.2020.11.017] [PMID: 33248395]
[36]
McFarthing, K.; Prakash, N.; Simuni, T. Phase 3 in focus - ampreloxetine, theravance biopharma. J. Parkinsons Dis., 2021, 11(2), 391-393.
[http://dx.doi.org/10.3233/JPD-219004] [PMID: 33749621]
[37]
Stavitsky, K.; Saurman, J.L.; McNamara, P.; Cronin-Golomb, A. Sleep in Parkinson’s disease: a comparison of actigraphy and subjective measures. Parkinsonism Relat. Disord., 2010, 16(4), 280-283.
[http://dx.doi.org/10.1016/j.parkreldis.2010.02.001] [PMID: 20202887]
[38]
Chahine, L.M.; Amara, A.W.; Videnovic, A. A systematic review of the literature on disorders of sleep and wakefulness in Parkinson’s disease from 2005 to 2015. Sleep Med. Rev., 2017, 35, 33-50.
[http://dx.doi.org/10.1016/j.smrv.2016.08.001] [PMID: 27863901]
[39]
Simuni, T.; Caspell-Garcia, C.; Coffey, C.S.; Weintraub, D.; Mollenhauer, B.; Lasch, S.; Tanner, C.M.; Jennings, D.; Kieburtz, K.; Chahine, L.M.; Marek, K. Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson’s disease: the PPMI cohort. J. Neurol. Neurosurg. Psychiatry, 2018, 89(1), 78-88.
[http://dx.doi.org/10.1136/jnnp-2017-316213] [PMID: 28986467]
[40]
Tholfsen, L.K.; Larsen, J.P.; Schulz, J.; Tysnes, O.B.; Gjerstad, M.D. Development of excessive daytime sleepiness in early Parkinson disease. Neurology, 2015, 85(2), 162-168.
[http://dx.doi.org/10.1212/WNL.0000000000001737] [PMID: 26085603]
[41]
Picillo, M.; Erro, R.; Amboni, M.; Longo, K.; Vitale, C.; Moccia, M.; Pierro, A.; Scannapieco, S.; Santangelo, G.; Spina, E.; Orefice, G.; Barone, P.; Pellecchia, M.T. Gender differences in non-motor symptoms in early Parkinson’s disease: a 2-years follow-up study on previously untreated patients. Parkinsonism Relat. Disord., 2014, 20(8), 850-854.
[http://dx.doi.org/10.1016/j.parkreldis.2014.04.023] [PMID: 24842702]
[42]
Erro, R.; Picillo, M.; Vitale, C.; Amboni, M.; Moccia, M.; Longo, K.; Cozzolino, A.; Giordano, F.; De Rosa, A.; De Michele, G.; Pellecchia, M.T.; Barone, P. Non-motor symptoms in early Parkinson’s disease: a 2-year follow-up study on previously untreated patients. J. Neurol. Neurosurg. Psychiatry, 2013, 84(1), 14-17.
[http://dx.doi.org/10.1136/jnnp-2012-303419] [PMID: 22993448]
[43]
Moccia, M.; Picillo, M.; Erro, R.; Vitale, C.; Longo, K.; Amboni, M.; Santangelo, G.; Palladino, R.; Capo, G.; Orefice, G.; Barone, P.; Pellecchia, M.T. Presence and progression of non-motor symptoms in relation to uric acid in de novo Parkinson’s disease. Eur. J. Neurol., 2015, 22(1), 93-98.
[http://dx.doi.org/10.1111/ene.12533] [PMID: 25104282]
[44]
Högl, B.; Stefani, A.; Videnovic, A. Idiopathic REM sleep behaviour disorder and neurodegeneration - an update. Nat. Rev. Neurol., 2018, 14(1), 40-55.
[http://dx.doi.org/10.1038/nrneurol.2017.157] [PMID: 29170501]
[45]
Friedman, J.H.; Beck, J.C.; Chou, K.L.; Clark, G.; Fagundes, C.P.; Goetz, C.G.; Herlofson, K.; Kluger, B.; Krupp, L.B.; Lang, A.E.; Lou, J.S.; Marsh, L.; Newbould, A.; Weintraub, D. Fatigue in Parkinson’s disease: report from a mutidisciplinary symposium. NPJ Parkinsons Dis., 2016, 2, 15025.
[http://dx.doi.org/10.1038/npjparkd.2015.25] [PMID: 27239558]
[46]
Ongre, S.O.; Larsen, J.P.; Tysnes, O.B.; Herlofson, K. Fatigue in early Parkinson’s disease: the Norwegian ParkWest study. Eur. J. Neurol., 2017, 24(1), 105-111.
[http://dx.doi.org/10.1111/ene.13161] [PMID: 27670392]
[47]
Woitalla, D.; Dunac, A.; Safavi, A.; Ceravolo, M.G.; Gomez Esteban, J.C.; Pavese, N.; Asgharnejad, M.; Joeres, L.; Schuller, J.C.; Chaudhuri, K.R. A noninterventional study evaluating the effectiveness of rotigotine and levodopa combination therapy in younger versus older patients with Parkinson’s disease. Expert Opin. Pharmacother., 2018, 19(9), 937-945.
[http://dx.doi.org/10.1080/14656566.2018.1480721] [PMID: 29916262]
[48]
Liguori, C.; Mercuri, N.B.; Albanese, M.; Olivola, E.; Stefani, A.; Pierantozzi, M. Daytime sleepiness may be an independent symptom unrelated to sleep quality in Parkinson’s disease. J. Neurol., 2019, 266(3), 636-641.
[http://dx.doi.org/10.1007/s00415-018-09179-8] [PMID: 30607535]
[49]
Yan, J.; Ma, H.; Liu, A.; Huang, J.; Wu, J.; Yang, J. Efficacy and safety of rotigotine transdermal patch on neuropsychiatric symptoms of Parkinson’s disease: An updated meta-analysis and systematic review. Front. Neurol., 2021, 12, 722892.
[http://dx.doi.org/10.3389/fneur.2021.722892] [PMID: 34744967]
[50]
Schrempf, W.; Fauser, M.; Wienecke, M.; Brown, S.; Maaß, A.; Ossig, C.; Otto, K.; Brandt, M.D.; Löhle, M.; Schwanebeck, U.; Graehlert, X.; Reichmann, H.; Storch, A. Rasagiline improves polysomnographic sleep parameters in patients with Parkinson’s disease: a double-blind, baseline-controlled trial. Eur. J. Neurol., 2018, 25(4), 672-679.
[http://dx.doi.org/10.1111/ene.13567] [PMID: 29322594]
[51]
Gilat, M.; Coeytaux, J.A.; Marshall, N.S.; Hammond, D.; Mullins, A.E.; Hall, J.M.; Fang, B.A.M.; Yee, B.J.; Wong, K.K.H.; Grunstein, R.R.; Lewis, S.J.G. Melatonin for rapid eye movement sleep behavior disorder in Parkinson’s disease: A randomised controlled trial. Mov. Disord., 2020, 35(2), 344-349.
[http://dx.doi.org/10.1002/mds.27886] [PMID: 31674060]
[52]
Delgado-Lara, D.L.; González-Enríquez, G.V.; Torres-Mendoza, B.M.; González-Usigli, H.; Cárdenas-Bedoya, J.; Macías-Islas, M.A.; de la Rosa, A.C.; Jiménez-Delgado, A.; Pacheco-Moisés, F.; Cruz-Serrano, J.A.; Ortiz, G.G. Effect of melatonin administration on the PER1 and BMAL1 clock genes in patients with Parkinson’s disease. Biomed. Pharmacother., 2020, 129, 110485.
[http://dx.doi.org/10.1016/j.biopha.2020.110485] [PMID: 32768967]
[53]
Rutten, S.; Vriend, C.; Smit, J.H.; Berendse, H.W.; van Someren, E.J.W.; Hoogendoorn, A.W.; Twisk, J.W.R.; van der Werf, Y.D.; van den Heuvel, O.A. Bright light therapy for depression in Parkinson disease: A randomized controlled trial. Neurology, 2019, 92(11), e1145-e1156.
[http://dx.doi.org/10.1212/WNL.0000000000007090] [PMID: 30770426]
[54]
Videnovic, A.; Klerman, E.B.; Wang, W.; Marconi, A.; Kuhta, T.; Zee, P.C. Timed light therapy for sleep and daytime sleepiness associated with Parkinson disease: A randomized clinical trial. JAMA Neurol., 2017, 74(4), 411-418.
[http://dx.doi.org/10.1001/jamaneurol.2016.5192] [PMID: 28241159]
[55]
Raymackers, J.M.; Andrade, M.; Baey, E.; Vanneste, M.; Evrard, F. Bright light therapy with a head-mounted device for anxiety, depression, sleepiness and fatigue in patients with Parkinson’s disease. Acta Neurol. Belg., 2019, 119(4), 607-613.
[http://dx.doi.org/10.1007/s13760-019-01214-3] [PMID: 31571135]
[56]
Kong, K.H.; Ng, H.L.; Li, W.; Ng, D.W.; Tan, S.I.; Tay, K.Y.; Au, W.L.; Tan, L.C.S. Acupuncture in the treatment of fatigue in Parkinson’s disease: A pilot, randomized, controlled, study. Brain Behav., 2017, 8(1), e00897.
[http://dx.doi.org/10.1002/brb3.897] [PMID: 29568693]
[57]
Walter, A.A.; Adams, E.V.; Van Puymbroeck, M.; Crowe, B.M.; Urrea-Mendoza, E.; Hawkins, B.L.; Sharp, J.; Woschkolup, K.; Revilla, F.J.; Schmid, A.A. Changes in nonmotor symptoms following an 8-week yoga intervention for people with Parkinson’s disease. Int. J. Yoga Therap., 2019, 29(1), 91-99.
[http://dx.doi.org/10.17761/2019-00025] [PMID: 30901529]
[58]
Atan, T.; Özyemişci, T.Ö.; Bora, T.A.; Kaymak, K.G.; Karakuş, Ç.A.; Karaoğlan, B. Effects of different percentages of body weight-supported treadmill training in Parkinson’s disease: a double-blind randomized controlled trial. Turk. J. Med. Sci., 2019, 49(4), 999-1007.
[http://dx.doi.org/10.3906/sag-1812-57] [PMID: 31292107]
[59]
Martinez-Martin, P.; Rizos, A.M.; Wetmore, J.B.; Antonini, A.; Odin, P.; Pal, S.; Sophia, R.; Carroll, C.; Martino, D.; Falup-Pecurariu, C.; Kessel, B.; Andrews, T.; Paviour, D.; Trenkwalder, C.; Chaudhuri, K.R. Relationship of nocturnal sleep dysfunction and pain subtypes in Parkinson’s disease. Mov. Disord. Clin. Pract. (Hoboken), 2018, 6(1), 57-64.
[http://dx.doi.org/10.1002/mdc3.12694] [PMID: 30746417]
[60]
St Louis, E.K.; Boeve, A.R.; Boeve, B.F. REM sleep behavior disorder in Parkinson’s disease and other synucleinopathies. Mov. Disord., 2017, 32(5), 645-658.
[http://dx.doi.org/10.1002/mds.27018] [PMID: 28513079]
[61]
Jenner, P.; Mori, A.; Aradi, S.D.; Hauser, R.A. Istradefylline - a first generation adenosine A2A antagonist for the treatment of Parkinson’s disease. Expert Rev. Neurother., 2021, 21(3), 317-333.
[http://dx.doi.org/10.1080/14737175.2021.1880896] [PMID: 33507105]
[62]
Smilowska, K.; van Wamelen, D.J.; Schoutens, A.M.C.; Meinders, M.J.; Bloem, B.R. Blue light therapy glasses in Parkinson’s disease: Patients’ experience. Parkinsons Dis., 2019, 2019, 1906271.
[http://dx.doi.org/10.1155/2019/1906271] [PMID: 31316746]
[63]
Xiang, W.; Sun, Y.Q.; Teoh, H.C. Comparison of nocturnal symptoms in advanced Parkinson’s disease patients with sleep disturbances: pramipexole sustained release versus immediate release formulations. Drug Des. Devel. Ther., 2018, 12, 2017-2024.
[http://dx.doi.org/10.2147/DDDT.S160300] [PMID: 30013321]
[64]
Zhang, H.; Gu, Z.; An, J.; Wang, C.; Chan, P. Non-motor symptoms in treated and untreated Chinese patients with early Parkinson’s disease. Tohoku J. Exp. Med., 2014, 232(2), 129-136.
[http://dx.doi.org/10.1620/tjem.232.129] [PMID: 24573063]
[65]
Chaudhuri, K.R.; Schapira, A.H. Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol., 2009, 8(5), 464-474.
[http://dx.doi.org/10.1016/S1474-4422(09)70068-7] [PMID: 19375664]
[66]
Burn, D.J. Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson’s disease. Mov. Disord., 2002, 17(3), 445-454.
[http://dx.doi.org/10.1002/mds.10114] [PMID: 12112190]
[67]
Brown, R.; Jahanshahi, M. Depression in Parkinson’s disease: a psychosocial viewpoint. Adv. Neurol., 1995, 65, 61-84.
[PMID: 7872153]
[68]
Cui, S.S.; Du, J.J.; Fu, R.; Lin, Y.Q.; Huang, P.; He, Y.C.; Gao, C.; Wang, H.L.; Chen, S.D. Prevalence and risk factors for depression and anxiety in Chinese patients with Parkinson disease. BMC Geriatr., 2017, 17(1), 270.
[http://dx.doi.org/10.1186/s12877-017-0666-2] [PMID: 29166864]
[69]
Reijnders, J.S.; Ehrt, U.; Weber, W.E.; Aarsland, D.; Leentjens, A.F. A systematic review of prevalence studies of depression in Parkinson’s disease. Mov. Disord., 2008, 23(2), 183-189.
[http://dx.doi.org/10.1002/mds.21803] [PMID: 17987654]
[70]
Tandberg, E.; Larsen, J.P.; Aarsland, D.; Cummings, J.L. The occurrence of depression in Parkinson’s disease. A community-based study. Arch. Neurol., 1996, 53(2), 175-179.
[http://dx.doi.org/10.1001/archneur.1996.00550020087019] [PMID: 8639068]
[71]
Ravina, B.; Elm, J.; Camicioli, R.; Como, P.G.; Marsh, L.; Jankovic, J.; Weintraub, D. The course of depressive symptoms in early Parkinson’s disease. Mov. Disord., 2009, 24(9), 1306-1311.
[http://dx.doi.org/10.1002/mds.22572] [PMID: 19412939]
[72]
Starkstein, S.E.; Mayberg, H.S.; Leiguarda, R.; Preziosi, T.J.; Robinson, R.G. A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry, 1992, 55(5), 377-382.
[http://dx.doi.org/10.1136/jnnp.55.5.377] [PMID: 1602311]
[73]
Chaudhuri, K.R.; Prieto-Jurcynska, C.; Naidu, Y.; Mitra, T.; Frades-Payo, B.; Tluk, S.; Ruessmann, A.; Odin, P.; Macphee, G.; Stocchi, F.; Ondo, W.; Sethi, K.; Schapira, A.H.; Martinez Castrillo, J.C.; Martinez-Martin, P. The nondeclaration of nonmotor symptoms of Parkinson’s disease to health care professionals: an international study using the nonmotor symptoms questionnaire. Mov. Disord., 2010, 25(6), 704-709.
[http://dx.doi.org/10.1002/mds.22868] [PMID: 20437539]
[74]
Dissanayaka, N.N.; Sellbach, A.; Matheson, S.; O’Sullivan, J.D.; Silburn, P.A.; Byrne, G.J.; Marsh, R.; Mellick, G.D. Anxiety disorders in Parkinson’s disease: prevalence and risk factors. Mov. Disord., 2010, 25(7), 838-845.
[http://dx.doi.org/10.1002/mds.22833] [PMID: 20461800]
[75]
Broen, M.P.; Narayen, N.E.; Kuijf, M.L.; Dissanayaka, N.N.; Leentjens, A.F. Prevalence of anxiety in Parkinson’s disease: A systematic review and meta-analysis. Mov. Disord., 2016, 31(8), 1125-1133.
[http://dx.doi.org/10.1002/mds.26643] [PMID: 27125963]
[76]
Cattaneo, C.; Müller, T.; Bonizzoni, E.; Lazzeri, G.; Kottakis, I.; Keywood, C. Long-term effects of safinamide on mood fluctuations in Parkinson’s disease. J. Parkinsons Dis., 2017, 7(4), 629-634.
[http://dx.doi.org/10.3233/JPD-171143] [PMID: 28777756]
[77]
Gershon, A.A.; Amiaz, R.; Shem-David, H.; Grunhaus, L. Ropinirole augmentation for depression: A randomized controlled trial pilot study. J. Clin. Psychopharmacol., 2019, 39(1), 78-81.
[http://dx.doi.org/10.1097/JCP.0000000000000984] [PMID: 30489382]
[78]
Takahashi, M.; Tabu, H.; Ozaki, A.; Hamano, T.; Takeshima, T. Antidepressants for depression, apathy, and gait instability in Parkinson’s disease: A multicenter randomized study. Intern. Med., 2019, 58(3), 361-368.
[http://dx.doi.org/10.2169/internalmedicine.1359-18] [PMID: 30146591]
[79]
Athauda, D.; Maclagan, K.; Budnik, N.; Zampedri, L.; Hibbert, S.; Skene, S.S.; Chowdhury, K.; Aviles-Olmos, I.; Limousin, P.; Foltynie, T. What effects might exenatide have on non-motor symptoms in Parkinson’s disease: A post hoc analysis. J. Parkinsons Dis., 2018, 8(2), 247-258.
[http://dx.doi.org/10.3233/JPD-181329] [PMID: 29843254]
[80]
Espay, A.J.; Guskey, M.T.; Norton, J.C.; Coate, B.; Vizcarra, J.A.; Ballard, C.; Factor, S.A.; Friedman, J.H.; Lang, A.E.; Larsen, N.J.; Andersson, C.; Fredericks, D.; Weintraub, D. Pimavanserin for Parkinson’s disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications. Mov. Disord., 2018, 33(11), 1769-1776.
[http://dx.doi.org/10.1002/mds.27488] [PMID: 30387904]
[81]
Isaacson, S.H.; Coate, B.; Norton, J.; Stankovic, S. Blinded SAPS-PD assessment after 10 weeks of pimavanserin treatment for Parkinson’s disease psychosis. J. Parkinsons Dis., 2020, 10(4), 1389-1396.
[http://dx.doi.org/10.3233/JPD-202047] [PMID: 32716320]
[82]
Isaacson, S.H.; Ballard, C.G.; Kreitzman, D.L.; Coate, B.; Norton, J.C.; Fernandez, H.H.; Ilic, T.V.; Azulay, J.P.; Ferreira, J.J.; Abler, V.; Stankovic, S. Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson’s disease psychosis patients. Parkinsonism Relat. Disord., 2021, 87, 25-31.
[http://dx.doi.org/10.1016/j.parkreldis.2021.04.012] [PMID: 33933853]
[83]
DeKarske, D.; Alva, G.; Aldred, J.L.; Coate, B.; Cantillon, M.; Jacobi, L.; Nunez, R.; Norton, J.C.; Abler, V. An open-label, 8-week study of safety and efficacy of pimavanserin treatment in adults with Parkinson’s disease and depression. J. Parkinsons Dis., 2020, 10(4), 1751-1761.
[http://dx.doi.org/10.3233/JPD-202058] [PMID: 32804101]
[84]
Manenti, R.; Cotelli, M.S.; Cobelli, C.; Gobbi, E.; Brambilla, M.; Rusich, D.; Alberici, A.; Padovani, A.; Borroni, B.; Cotelli, M. Transcranial direct current stimulation combined with cognitive training for the treatment of Parkinson Disease: A randomized, placebo-controlled study. Brain Stimul., 2018, 11(6), 1251-1262.
[http://dx.doi.org/10.1016/j.brs.2018.07.046] [PMID: 30056141]
[85]
Dobbs, B.; Pawlak, N.; Biagioni, M.; Agarwal, S.; Shaw, M.; Pilloni, G.; Bikson, M.; Datta, A.; Charvet, L. Generalizing remotely supervised transcranial direct current stimulation (tDCS): feasibility and benefit in Parkinson’s disease. J. Neuroeng. Rehabil., 2018, 15(1), 114.
[http://dx.doi.org/10.1186/s12984-018-0457-9] [PMID: 30522497]
[86]
Cohen, O.S.; Rigbi, A.; Yahalom, G.; Warman-Alaluf, N.; Nitsan, Z.; Zangen, A.; Hassin-Baer, S. Repetitive deep TMS for Parkinson disease: A 3-month double-blind, randomized sham-controlled study. J. Clin. Neurophysiol., 2018, 35(2), 159-165.
[http://dx.doi.org/10.1097/WNP.0000000000000455] [PMID: 29373395]
[87]
Wuthrich, V.M.; Rapee, R.M. Telephone-delivered cognitive behavioural therapy for treating symptoms of anxiety and depression in Parkinson’s disease: A pilot trial. Clin. Gerontol., 2019, 42(4), 444-453.
[http://dx.doi.org/10.1080/07317115.2019.1580811] [PMID: 30821649]
[88]
Dobkin, R.D.; Mann, S.L.; Gara, M.A.; Interian, A.; Rodriguez, K.M.; Menza, M. Telephone-based cognitive behavioral therapy for depression in Parkinson disease: A randomized controlled trial. Neurology, 2020, 94(16), e1764-e1773.
[http://dx.doi.org/10.1212/WNL.0000000000009292] [PMID: 32238507]
[89]
Goedeken, S.; Potempa, C.; Prager, E.M.; Foster, E.R. Encoding strategy training and self-reported everyday prospective memory in people with Parkinson disease: a randomized-controlled trial. Clin. Neuropsychol., 2018, 32(7), 1282-1302.
[http://dx.doi.org/10.1080/13854046.2017.1387287] [PMID: 29029571]
[90]
Fellman, D.; Salmi, J.; Ritakallio, L.; Ellfolk, U.; Rinne, J.O.; Laine, M. Training working memory updating in Parkinson’s disease: A randomised controlled trial. Neuropsychol. Rehabil., 2020, 30(4), 673-708.
[http://dx.doi.org/10.1080/09602011.2018.1489860] [PMID: 29968519]
[91]
Birtwell, K.; Dubrow-Marshall, L.; Dubrow-Marshall, R.; Duerden, T.; Dunn, A. A mixed methods evaluation of a Mindfulness-Based Stress Reduction course for people with Parkinson’s disease. Complement. Ther. Clin. Pract., 2017, 29, 220-228.
[http://dx.doi.org/10.1016/j.ctcp.2017.10.009] [PMID: 29122265]
[92]
Rodgers, S.H.; Schütze, R.; Gasson, N.; Anderson, R.A.; Kane, R.T.; Starkstein, S.; Morgan-Lowes, K.; Egan, S.J. Modified mindfulness-based cognitive therapy for depressive symptoms in Parkinson’s disease: a Pilot Trial. Behav. Cogn. Psychother., 2019, 47(4), 446-461.
[http://dx.doi.org/10.1017/S135246581800070X] [PMID: 30654854]
[93]
Cho, S.Y.; Lee, Y.E.; Doo, K.H.; Lee, J.H.; Jung, W.S.; Moon, S.K.; Park, J.M.; Ko, C.N.; Kim, H.; Rhee, H.Y.; Park, H.J.; Park, S.U. Efficacy of combined treatment with acupuncture and bee venom acupuncture as an adjunctive treatment for Parkinson’s disease. J. Altern. Complement. Med., 2018, 24(1), 25-32.
[http://dx.doi.org/10.1089/acm.2016.0250] [PMID: 28753030]
[94]
Pohl, P.; Wressle, E.; Lundin, F.; Enthoven, P.; Dizdar, N. Group-based music intervention in Parkinson’s disease - findings from a mixed-methods study. Clin. Rehabil., 2020, 34(4), 533-544.
[http://dx.doi.org/10.1177/0269215520907669] [PMID: 32070122]
[95]
Bega, D.; Palmentera, P.; Wagner, A.; Hovde, M.; Barish, B.; Kwasny, M.J.; Simuni, T. Laughter is the best medicine: The Second City® improvisation as an intervention for Parkinson’s disease. Parkinsonism Relat. Disord., 2017, 34, 62-65.
[http://dx.doi.org/10.1016/j.parkreldis.2016.11.001] [PMID: 27836715]
[96]
de Lima, T.A.; Ferreira-Moraes, R.; Alves, W.M.G.D.C.; Alves, T.G.G.; Pimentel, C.P.; Sousa, E.C.; Abrahin, O.; Cortinhas-Alves, E.A. Resistance training reduces depressive symptoms in elderly people with Parkinson disease: A controlled randomized study. Scand. J. Med. Sci. Sports, 2019, 29(12), 1957-1967.
[http://dx.doi.org/10.1111/sms.13528] [PMID: 31357229]
[97]
Tollár, J.; Nagy, F.; Hortobágyi, T. Vastly different exercise programs similarly improve Parkinsonian symptoms: A randomized clinical trial. Gerontology, 2019, 65(2), 120-127.
[http://dx.doi.org/10.1159/000493127] [PMID: 30368495]
[98]
Harper, S.A.; Dowdell, B.T.; Kim, J.H.; Pollock, B.S.; Ridgel, A.L. Non-motor symptoms after one week of high cadence cycling in Parkinson’s disease. Int. J. Environ. Res. Public Health, 2019, 16(12), 2104.
[http://dx.doi.org/10.3390/ijerph16122104] [PMID: 31197095]
[99]
Kwok, J.Y.Y.; Kwan, J.C.Y.; Auyeung, M.; Mok, V.C.T.; Lau, C.K.Y.; Choi, K.C.; Chan, H.Y.L. Effects of mindfulness yoga vs stretching and resistance training exercises on anxiety and depression for people with Parkinson disease: A randomized clinical trial. JAMA Neurol., 2019, 76(7), 755-763.
[http://dx.doi.org/10.1001/jamaneurol.2019.0534] [PMID: 30958514]
[100]
Burt, J.; Ravid, E.N.; Bradford, S.; Fisher, N.J.; Zeng, Y.; Chomiak, T.; Brown, L.; McKeown, M.J.; Hu, B.; Camicioli, R. The effects of music-contingent gait training on cognition and mood in parkinson disease: A feasibility study. Neurorehabil. Neural Repair, 2020, 34(1), 82-92.
[http://dx.doi.org/10.1177/1545968319893303] [PMID: 31878824]
[101]
Solla, P.; Cugusi, L.; Bertoli, M.; Cereatti, A.; Della Croce, U.; Pani, D.; Fadda, L.; Cannas, A.; Marrosu, F.; Defazio, G.; Mercuro, G. Sardinian folk dance for individuals with Parkinson’s disease: a randomized controlled pilot trial. J. Altern. Complement. Med., 2019, 25(3), 305-316.
[http://dx.doi.org/10.1089/acm.2018.0413] [PMID: 30624952]
[102]
Kalyani, H.H.N.; Sullivan, K.A.; Moyle, G.; Brauer, S.; Jeffrey, E.R.; Kerr, G.K. Impacts of dance on cognition, psychological symptoms and quality of life in Parkinson’s disease. NeuroRehabilitation, 2019, 45(2), 273-283.
[http://dx.doi.org/10.3233/NRE-192788] [PMID: 31561398]
[103]
Lee, H.J.; Kim, S.Y.; Chae, Y.; Kim, M.Y.; Yin, C.; Jung, W.S.; Cho, K.H.; Kim, S.N.; Park, H.J.; Lee, H. Turo (Qi Dance) program for Parkinson’s disease patients: randomized, assessor blind, waiting-list control, partial crossover study. Explore (NY), 2018, 14(3), 216-223.
[http://dx.doi.org/10.1016/j.explore.2017.11.002] [PMID: 29650371]
[104]
Zhu, M.; Zhang, Y.; Pan, J.; Fu, C.; Wang, Y. Effect of simplified Tai Chi exercise on relieving symptoms of patients with mild to moderate Parkinson’s disease. J. Sports Med. Phys. Fitness, 2020, 60(2), 282-288.
[http://dx.doi.org/10.23736/S0022-4707.19.10104-1] [PMID: 31665879]
[105]
Fleisher, J.E.; Sennott, B.J.; Myrick, E.; Niemet, C.J.; Lee, M.; Whitelock, C.M.; Sanghvi, M.; Liu, Y.; Ouyang, B.; Hall, D.A.; Comella, C.L.; Chodosh, J. kick out PD: Feasibility and quality of life in the pilot karate intervention to change kinematic outcomes in Parkinson’s Disease. PLoS One, 2020, 15(9), e0237777.
[http://dx.doi.org/10.1371/journal.pone.0237777] [PMID: 32903267]
[106]
Gallagher, D.A.; Schrag, A. Psychosis, apathy, depression and anxiety in Parkinson’s disease. Neurobiol. Dis., 2012, 46(3), 581-589.
[http://dx.doi.org/10.1016/j.nbd.2011.12.041] [PMID: 22245219]
[107]
Weintraub, D.; Moberg, P.J.; Duda, J.E.; Katz, I.R.; Stern, M.B. Recognition and treatment of depression in Parkinson’s disease. J. Geriatr. Psychiatry Neurol., 2003, 16(3), 178-183.
[http://dx.doi.org/10.1177/0891988703256053] [PMID: 12967062]
[108]
Richard, I.H.; Kurlan, R. A survey of antidepressant drug use in Parkinson’s disease. Neurology, 1997, 49(4), 1168-1170.
[http://dx.doi.org/10.1212/WNL.49.4.1168] [PMID: 9339713]
[109]
Storch, A.; Rosqvist, K.; Ebersbach, G.; Odin, P. Disease stage dependency of motor and non-motor fluctuations in Parkinson’s disease. J. Neural Transm. (Vienna), 2019, 126(7), 841-851.
[http://dx.doi.org/10.1007/s00702-019-02033-9] [PMID: 31218469]
[110]
Rosqvist, K.; Odin, P.; Hagell, P.; Iwarsson, S.; Nilsson, M.H.; Storch, A. Dopaminergic Effect on Non-Motor Symptoms in Late Stage Parkinson’s Disease. J. Parkinsons Dis., 2018, 8(3), 409-420.
[http://dx.doi.org/10.3233/JPD-181380] [PMID: 30056433]
[111]
Classen, J.; Koschel, J.; Oehlwein, C.; Seppi, K.; Urban, P.; Winkler, C.; Wüllner, U.; Storch, A. Nonmotor fluctuations: phenotypes, pathophysiology, management, and open issues. J. Neural Transm. (Vienna), 2017, 124(8), 1029-1036.
[http://dx.doi.org/10.1007/s00702-017-1757-0] [PMID: 28702850]
[112]
van Wamelen, D.J.; Grigoriou, S.; Chaudhuri, K.R.; Odin, P. Continuous drug delivery aiming continuous dopaminergic stimulation in Parkinson’s disease. J. Parkinsons Dis., 2018, 8(s1), S65-S72.
[http://dx.doi.org/10.3233/JPD-181476] [PMID: 30584160]
[113]
Chaudhuri, K.R.; Qamar, M.A.; Rajah, T.; Loehrer, P.; Sauerbier, A.; Odin, P.; Jenner, P. Non-oral dopaminergic therapies for Parkinson’s disease: Current treatments and the future. NPJ Parkinsons Dis., 2016, 2, 16023.
[http://dx.doi.org/10.1038/npjparkd.2016.23] [PMID: 28725704]
[114]
Martinez-Martin, P.; Reddy, P.; Katzenschlager, R.; Antonini, A.; Todorova, A.; Odin, P.; Henriksen, T.; Martin, A.; Calandrella, D.; Rizos, A.; Bryndum, N.; Glad, A.; Dafsari, H.S.; Timmermann, L.; Ebersbach, G.; Kramberger, M.G.; Samuel, M.; Wenzel, K.; Tomantschger, V.; Storch, A.; Reichmann, H.; Pirtosek, Z.; Trost, M.; Svenningsson, P.; Palhagen, S.; Volkmann, J.; Chaudhuri, K.R. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson’s disease. Mov. Disord., 2015, 30(4), 510-516.
[http://dx.doi.org/10.1002/mds.26067] [PMID: 25382161]
[115]
Hwang, Y.J.; Alexander, G.C.; An, H.; Moore, T.J.; Mehta, H.B. Risk of hospitalization and death associated with pimavanserin use in older adults with Parkinson disease. Neurology, 2021, 97(13), e1266-e1275.
[http://dx.doi.org/10.1212/WNL.0000000000012601] [PMID: 34389652]
[116]
Estevao, C.; Fancourt, D.; Dazzan, P.; Chaudhuri, K.R.; Sevdalis, N.; Woods, A.; Crane, N.; Bind, R.; Sawyer, K.; Rebecchini, L.; Hazelgrove, K.; Manoharan, M.; Burton, A.; Dye, H.; Osborn, T.; Jarrett, L.; Ward, N.; Jones, F.; Podlewska, A.; Premoli, I.; Derbyshire-Fox, F.; Hartley, A.; Soukup, T.; Davis, R.; Bakolis, I.; Healey, A.; Pariante, C.M. Scaling-up Health-Arts Programmes: the largest study in the world bringing arts-based mental health interventions into a national health service. BJPsych Bull., 2021, 45(1), 32-39.
[http://dx.doi.org/10.1192/bjb.2020.122] [PMID: 33355526]
[117]
Bruno, V.; Freitas, M.E.; Mancini, D.; Lui, J.P.; Miyasaki, J.; Fox, S.H. Botulinum toxin type A for pain in advanced Parkinson’s disease. Can. J. Neurol. Sci., 2018, 45(1), 23-29.
[http://dx.doi.org/10.1017/cjn.2017.245] [PMID: 29334040]
[118]
Cattaneo, C.; Barone, P.; Bonizzoni, E.; Sardina, M. Effects of safinamide on pain in fluctuating Parkinson’s disease patients: A post-hoc analysis. J. Parkinsons Dis., 2017, 7(1), 95-101.
[http://dx.doi.org/10.3233/JPD-160911] [PMID: 27802242]
[119]
Cattaneo, C.; Kulisevsky, J.; Tubazio, V.; Castellani, P. Long-term efficacy of safinamide on Parkinson’s disease chronic pain. Adv. Ther., 2018, 35(4), 515-522.
[http://dx.doi.org/10.1007/s12325-018-0687-z] [PMID: 29542008]
[120]
Grigoriou, S.; Martínez-Martín, P.; Ray Chaudhuri, K.; Rukavina, K.; Leta, V.; Hausbrand, D.; Falkenburger, B.; Odin, P.; Reichmann, H. Effects of safinamide on pain in patients with fluctuating Parkinson’s disease. Brain Behav., 2021, 11(10), e2336.
[http://dx.doi.org/10.1002/brb3.2336] [PMID: 34478245]
[121]
Timmermann, L.; Oehlwein, C.; Ransmayr, G.; Fröhlich, H.; Will, E.; Schroeder, H.; Lauterbach, T.; Bauer, L.; Kassubek, J. Patients’ perception of Parkinson’s disease-associated pain following initiation of rotigotine: a multicenter non-interventional study. Postgrad. Med., 2017, 129(1), 46-54.
[http://dx.doi.org/10.1080/00325481.2017.1258953] [PMID: 27883297]
[122]
Rascol, O.; Zesiewicz, T.; Chaudhuri, K.R.; Asgharnejad, M.; Surmann, E.; Dohin, E.; Nilius, S.; Bauer, L. A randomized controlled exploratory pilot study to evaluate the effect of rotigotine transdermal patch on Parkinson’s disease-associated chronic pain. J. Clin. Pharmacol., 2016, 56(7), 852-861.
[http://dx.doi.org/10.1002/jcph.678] [PMID: 26626320]
[123]
Rukavina, K.; Cummins, T.M.; Chaudhuri, K.R.; Bannister, K. Pain in Parkinson’s disease: Mechanism-based treatment strategies. Curr. Opin. Support. Palliat. Care, 2021, 15(2), 108-115.
[http://dx.doi.org/10.1097/SPC.0000000000000546] [PMID: 33782333]
[124]
Pérez de la Cruz, S. Effectiveness of aquatic therapy for the control of pain and increased functionality in people with Parkinson’s disease: a randomized clinical trial. Eur. J. Phys. Rehabil. Med., 2017, 53(6), 825-832.
[http://dx.doi.org/10.23736/S1973-9087.17.04647-0] [PMID: 28627861]
[125]
Rukavina, K.; Batzu, L.; Leta, V.; Chaudhuri, K.R. New approaches to treatments for sleep, pain and autonomic failure in Parkinson’s disease - pharmacological therapies. Neuropharmacology, 2022, 208, 108959.
[http://dx.doi.org/10.1016/j.neuropharm.2022.108959] [PMID: 35051446]
[126]
Trenkwalder, C.; Kies, B.; Rudzinska, M.; Fine, J.; Nikl, J.; Honczarenko, K.; Dioszeghy, P.; Hill, D.; Anderson, T.; Myllyla, V.; Kassubek, J.; Steiger, M.; Zucconi, M.; Tolosa, E.; Poewe, W.; Surmann, E.; Whitesides, J.; Boroojerdi, B.; Chaudhuri, K.R. Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov. Disord., 2011, 26(1), 90-99.
[http://dx.doi.org/10.1002/mds.23441] [PMID: 21322021]
[127]
Kassubek, J.; Chaudhuri, K.R.; Zesiewicz, T.; Surmann, E.; Boroojerdi, B.; Moran, K.; Ghys, L.; Trenkwalder, C. Rotigotine transdermal system and evaluation of pain in patients with Parkinson’s disease: a post hoc analysis of the RECOVER study. BMC Neurol., 2014, 14, 42.
[http://dx.doi.org/10.1186/1471-2377-14-42] [PMID: 24602411]
[128]
Trenkwalder, C.; Chaudhuri, K.R.; Martinez-Martin, P.; Rascol, O.; Ehret, R.; Vališ, M.; Sátori, M.; Krygowska-Wajs, A.; Marti, M.J.; Reimer, K.; Oksche, A.; Lomax, M.; DeCesare, J.; Hopp, M. Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson’s disease (PANDA): a double-blind, randomised, placebo-controlled trial. Lancet Neurol., 2015, 14(12), 1161-1170.
[http://dx.doi.org/10.1016/S1474-4422(15)00243-4] [PMID: 26494524]
[129]
Smilowska, K.; van Wamelen, D.J.; Pietrzykowski, T.; Calvano, A.; Rodriguez-Blazquez, C.; Martinez-Martin, P.; Odin, P.; Chaudhuri, K.R. Cost-effectiveness of device-aided therapies in Parkinson’s disease: A structured review. J. Parkinsons Dis., 2021, 11(2), 475-489.
[http://dx.doi.org/10.3233/JPD-202348] [PMID: 33386813]
[130]
Prakash, N.; Simuni, T. Infusion therapies for Parkinson’s disease. Curr. Neurol. Neurosci. Rep., 2020, 20(9), 44.
[http://dx.doi.org/10.1007/s11910-020-01062-2] [PMID: 32740768]
[131]
Antonini, A.; Stoessl, A.J.; Kleinman, L.S.; Skalicky, A.M.; Marshall, T.S.; Sail, K.R.; Onuk, K.; Odin, P.L.A. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson’s disease: a multi-country Delphi-panel approach. Curr. Med. Res. Opin., 2018, 34(12), 2063-2073.
[http://dx.doi.org/10.1080/03007995.2018.1502165] [PMID: 30016901]
[132]
Dafsari, H.S.; Martinez-Martin, P.; Rizos, A.; Trost, M.; Dos Santos Ghilardi, M.G.; Reddy, P.; Sauerbier, A.; Petry-Schmelzer, J.N.; Kramberger, M.; Borgemeester, R.W.K.; Barbe, M.T.; Ashkan, K.; Silverdale, M.; Evans, J.; Odin, P.; Fonoff, E.T.; Fink, G.R.; Henriksen, T.; Ebersbach, G.; Pirtošek, Z.; Visser-Vandewalle, V.; Antonini, A.; Timmermann, L.; Ray Chaudhuri, K. EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson’s disease. Mov. Disord., 2019, 34(3), 353-365.
[http://dx.doi.org/10.1002/mds.27626] [PMID: 30719763]
[133]
Antonini, A.; Odin, P.; Alobaidi, A.; Cubillos, F.; Schmidt, P.N.; Jalundhwala, Y.J.; Onuk, K.; Zamudio, J.; Kukreja, P.K.; Jones, E.; Wright, J.; Fernandez, H. Demonstrating the clinical value of MANAGE-PD tool in assessing symptom control of Parkinson’s disease patients: Evidence from G7 Countries. Mov Disord., 2020, 35(suppl 1) Available from: https://www.mdsabstracts.org/abstract/demonstrating-the-clinical-value-of-manage-pd-tool-in-assessingsymptom-control-of-parkinsons-disease-patients-evidence-fromg7-countries Accessed March 21, 2022.
[134]
Leta, V.; Dafsari, H.S.; Sauerbier, A.; Metta, V.; Titova, N.; Timmermann, L.; Ashkan, K.; Samuel, M.; Pekkonen, E.; Odin, P.; Antonini, A.; Martinez-Martin, P.; Parry, M.; van Wamelen, D.J.; Ray Chaudhuri, K. Personalised advanced therapies in Parkinson’s disease: The role of non-motor symptoms profile. J. Pers. Med., 2021, 11(8), 773.
[http://dx.doi.org/10.3390/jpm11080773] [PMID: 34442417]
[135]
Jost, S.T.; Sauerbier, A.; Visser-Vandewalle, V.; Ashkan, K.; Silverdale, M.; Evans, J.; Loehrer, P.A.; Rizos, A.; Petry-Schmelzer, J.N.; Reker, P.; Fink, G.R.; Franklin, J.; Samuel, M.; Schnitzler, A.; Barbe, M.T.; Antonini, A.; Martinez-Martin, P.; Timmermann, L.; Ray-Chaudhuri, K.; Dafsari, H.S. A prospective, controlled study of non-motor effects of subthalamic stimulation in Parkinson’s disease: results at the 36-month follow-up. J. Neurol. Neurosurg. Psychiatry, 2020, 91(7), 687-694.
[http://dx.doi.org/10.1136/jnnp-2019-322614] [PMID: 32371534]
[136]
Dafsari, H.S.; Petry-Schmelzer, J.N.; Ray-Chaudhuri, K.; Ashkan, K.; Weis, L.; Dembek, T.A.; Samuel, M.; Rizos, A.; Silverdale, M.; Barbe, M.T.; Fink, G.R.; Evans, J.; Martinez-Martin, P.; Antonini, A.; Visser-Vandewalle, V.; Timmermann, L. Non-motor outcomes of subthalamic stimulation in Parkinson’s disease depend on location of active contacts. Brain Stimul., 2018, 11(4), 904-912.
[http://dx.doi.org/10.1016/j.brs.2018.03.009] [PMID: 29655586]
[137]
Bardon, J.; Kurcova, S.; Chudackova, M.; Otruba, P.; Krahulik, D.; Nevrly, M.; Kanovsky, P.; Zapletalova, J.; Valosek, J.; Hlustik, P.; Vastik, M.; Vecerkova, M.; Hvizdosova, L.; Mensikova, K.; Kurca, E.; Sivak, S. Deep brain stimulation electrode position impact on parkinsonian non-motor symptoms. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub., 2022, 166(1), 57-62.
[http://dx.doi.org/10.5507/bp.2020.034] [PMID: 33883752]
[138]
Cartmill, T.; Skvarc, D.; Bittar, R.; McGillivray, J.; Berk, M.; Byrne, L.K. Deep brain stimulation of the subthalamic nucleus in Parkinson’s disease: a meta-analysis of mood effects. Neuropsychol. Rev., 2021, 31(3), 385-401.
[http://dx.doi.org/10.1007/s11065-020-09467-z] [PMID: 33606174]
[139]
Birchall, E.L.; Walker, H.C.; Cutter, G.; Guthrie, S.; Joop, A.; Memon, R.A.; Watts, R.L.; Standaert, D.G.; Amara, A.W. The effect of unilateral subthalamic nucleus deep brain stimulation on depression in Parkinson’s disease. Brain Stimul., 2017, 10(3), 651-656.
[http://dx.doi.org/10.1016/j.brs.2016.12.014] [PMID: 28065487]
[140]
Zhang, X.; Xie, A. Improvement of subthalamic nucleus deep brain stimulation in sleeping symptoms in Parkinson’s disease: A meta-analysis. Parkinsons Dis., 2019, 2019, 6280896.
[http://dx.doi.org/10.1155/2019/6280896] [PMID: 31687125]
[141]
Cavalloni, F.; Debove, I.; Lachenmayer, M.L.; Krack, P.; Pollo, C.; Schuepbach, W.M.M.; Bassetti, C.L.A.; Bargiotas, P. A case series and systematic review of rapid eye movement sleep behavior disorder outcome after deep brain stimulation in Parkinson’s disease. Sleep Med., 2021, 77, 170-176.
[http://dx.doi.org/10.1016/j.sleep.2020.11.025] [PMID: 33412362]
[142]
Maheshwary, A.; Mohite, D.; Omole, J.A.; Bhatti, K.S.; Khan, S. Is deep brain stimulation associated with detrimental effects on cognitive functions in patients of Parkinson’s disease? A systematic review. Cureus, 2020, 12(8), e9688.
[http://dx.doi.org/10.7759/cureus.9688] [PMID: 32923280]
[143]
Bellini, G.; Best, L.A.; Brechany, U.; Mills, R.; Pavese, N. Clinical Impact of Deep Brain Stimulation on the Autonomic System in Patients with Parkinson’s Disease. Mov. Disord. Clin. Pract. (Hoboken), 2020, 7(4), 373-382.
[http://dx.doi.org/10.1002/mdc3.12938] [PMID: 32373653]
[144]
DiMarzio, M.; Rashid, T.; Hancu, I.; Fiveland, E.; Prusik, J.; Gillogly, M.; Madhavan, R.; Joel, S.; Durphy, J.; Molho, E.; Hanspal, E.; Shin, D.; Pilitsis, J.G. Functional MRI signature of chronic pain relief from deep brain stimulation in Parkinson Disease patients. Neurosurgery, 2019, 85(6), E1043-E1049.
[http://dx.doi.org/10.1093/neuros/nyz269] [PMID: 31313816]
[145]
DiMarzio, M.; Pilitsis, J.G.; Gee, L.; Peng, S.; Prusik, J.; Durphy, J.; Ramirez-Zamora, A.; Hanspal, E.; Molho, E.; McCallum, S.E. King’s Parkinson’s disease pain scale for assessment of pain relief following deep brain stimulation for Parkinson’s disease. Neuromodulation, 2018, 21(6), 617-622.
[http://dx.doi.org/10.1111/ner.12778] [PMID: 29608802]
[146]
Saatçi, Ö.; Yılmaz, N.H.; Zırh, A.; Yulug, B. The therapeutic effect of deep brain stimulation on olfactory functions and clinical scores in Parkinson’s disease. J. Clin. Neurosci., 2019, 68, 55-61.
[http://dx.doi.org/10.1016/j.jocn.2019.07.055] [PMID: 31383472]
[147]
Rosa-Grilo, M.; Qamar, M.A.; Evans, A.; Chaudhuri, K.R. The efficacy of apomorphine - A non-motor perspective. Parkinsonism Relat. Disord., 2016, 33(S1)(Suppl. 1), S28-S35.
[http://dx.doi.org/10.1016/j.parkreldis.2016.11.020] [PMID: 27939325]
[148]
Katzenschlager, R.; Poewe, W.; Rascol, O.; Trenkwalder, C.; Deuschl, G.; Chaudhuri, K.R.; Henriksen, T.; van Laar, T.; Lockhart, D.; Staines, H.; Lees, A. Long-term safety and efficacy of apomorphine infusion in Parkinson’s disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study. Parkinsonism Relat. Disord., 2021, 83, 79-85.
[http://dx.doi.org/10.1016/j.parkreldis.2020.12.024] [PMID: 33486139]
[149]
Katzenschlager, R.; Poewe, W.; Rascol, O.; Trenkwalder, C.; Deuschl, G.; Chaudhuri, K.R.; Henriksen, T.; van Laar, T.; Spivey, K.; Vel, S.; Staines, H.; Lees, A. Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol., 2018, 17(9), 749-759.
[http://dx.doi.org/10.1016/S1474-4422(18)30239-4] [PMID: 30055903]
[150]
Antonini, A.; Odin, P.; Pahwa, R.; Aldred, J.; Alobaidi, A.; Jalundhwala, Y.J.; Kukreja, P.; Bergmann, L.; Inguva, S.; Bao, Y.; Chaudhuri, K.R. The long-term impact of levodopa/carbidopa intestinal gel on ‘off’-time in patients with advanced Parkinson’s disease: A systematic review. Adv. Ther., 2021, 38(6), 2854-2890.
[http://dx.doi.org/10.1007/s12325-021-01747-1] [PMID: 34018146]
[151]
Antonini, A.; Poewe, W.; Chaudhuri, K.R.; Jech, R.; Pickut, B.; Pirtošek, Z.; Szasz, J.; Valldeoriola, F.; Winkler, C.; Bergmann, L.; Yegin, A.; Onuk, K.; Barch, D.; Odin, P. Levodopa-carbidopa intestinal gel in advanced Parkinson’s: Final results of the GLORIA registry. Parkinsonism Relat. Disord., 2017, 45, 13-20.
[http://dx.doi.org/10.1016/j.parkreldis.2017.09.018] [PMID: 29037498]
[152]
Aldred, J.; Anca-Herschkovitsch, M.; Antonini, A.; Bajenaru, O.; Bergmann, L.; Bourgeois, P.; Cubo, E.; Davis, T.L.; Iansek, R.; Kovács, N.; Kukreja, P.; Onuk, K.; Pontieri, F.E.; Robieson, W.; Siddiqui, M.S.; Simu, M.; Standaert, D.G.; Chaudhuri, K.R. Application of the ‘5-2-1’ screening criteria in advanced Parkinson’s disease: interim analysis of duoglobe. Neurodegener. Dis. Manag., 2020, 10(5), 309-323.
[http://dx.doi.org/10.2217/nmt-2020-0021] [PMID: 32873195]
[153]
Ray Chaudhuri, K.; Antonini, A.; Robieson, W.Z.; Sanchez-Soliño, O.; Bergmann, L.; Poewe, W. Burden of non-motor symptoms in Parkinson’s disease patients predicts improvement in quality of life during treatment with levodopa-carbidopa intestinal gel. Eur. J. Neurol., 2019, 26(4), 581-e43.
[http://dx.doi.org/10.1111/ene.13847] [PMID: 30353942]
[154]
Kulisevsky, J.; Bejr-Kasem, H.; Martinez-Horta, S.; Horta-Barba, A.; Pascual-Sedano, B.; Campolongo, A.; Marín-Lahoz, J.; Aracil-Bolaños, I.; Pérez-Pérez, J.; Izquierdo-Barrionuevo, C.; de Fàbregues, O.; Puente, V.; Crespo-Cuevas, A.; Calopa, M.; Pagonabarraga, J. Subclinical affective and cognitive fluctuations in Parkinson’s disease: a randomized double-blind double-dummy study of Oral vs. Intrajejunal Levodopa. J. Neurol., 2020, 267(11), 3400-3410.
[http://dx.doi.org/10.1007/s00415-020-10018-y] [PMID: 32607644]
[155]
Standaert, D.G.; Rodriguez, R.L.; Slevin, J.T.; Lobatz, M.; Eaton, S.; Chatamra, K.; Facheris, M.F.; Hall, C.; Sail, K.; Jalundhwala, Y.J.; Benesh, J. Effect of levodopa-carbidopa intestinal gel on non-motor symptoms in patients with advanced Parkinson’s disease. Mov. Disord. Clin. Pract. (Hoboken), 2017, 4(6), 829-837.
[http://dx.doi.org/10.1002/mdc3.12526] [PMID: 29242809]
[156]
Honig, H.; Antonini, A.; Martinez-Martin, P.; Forgacs, I.; Faye, G.C.; Fox, T.; Fox, K.; Mancini, F.; Canesi, M.; Odin, P.; Chaudhuri, K.R. Intrajejunal levodopa infusion in Parkinson’s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov. Disord., 2009, 24(10), 1468-1474.
[http://dx.doi.org/10.1002/mds.22596] [PMID: 19425079]
[157]
Leta, V.; van Wamelen, D.J.; Sauerbier, A.; Jones, S.; Parry, M.; Rizos, A.; Chaudhuri, K.R. Opicapone and levodopa-carbidopa intestinal gel infusion: The way forward towards cost savings for healthcare systems? J. Parkinsons Dis., 2020, 10(4), 1535-1539.
[http://dx.doi.org/10.3233/JPD-202022] [PMID: 32597817]
[158]
Öthman, M.; Widman, E.; Nygren, I.; Nyholm, D. Initial experience of the levodopa-entacapone-carbidopa intestinal gel in clinical practice. J. Pers. Med., 2021, 11(4), 254.
[http://dx.doi.org/10.3390/jpm11040254] [PMID: 33807308]
[159]
Lhommée, E.; Wojtecki, L.; Czernecki, V.; Witt, K.; Maier, F.; Tonder, L.; Timmermann, L.; Hälbig, T.D.; Pineau, F.; Durif, F.; Witjas, T.; Pinsker, M.; Mehdorn, M.; Sixel-Döring, F.; Kupsch, A.; Krüger, R.; Elben, S.; Chabardès, S.; Thobois, S.; Brefel-Courbon, C.; Ory-Magne, F.; Regis, J.M.; Maltête, D.; Sauvaget, A.; Rau, J.; Schnitzler, A.; Schüpbach, M.; Schade-Brittinger, C.; Deuschl, G.; Houeto, J.L.; Krack, P. Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson’s disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial. Lancet Neurol., 2018, 17(3), 223-231.
[http://dx.doi.org/10.1016/S1474-4422(18)30035-8] [PMID: 29452685]
[160]
Pieper, D.; Mathes, T. Survey of instructions for authors on how to report an update of a systematic review: guidance is needed. Evid. Based Med., 2017, 22(2), 45-48.
[http://dx.doi.org/10.1136/ebmed-2016-110609] [PMID: 28137732]
[161]
Wang, H.T.; Wang, L.; He, Y.; Yu, G. Rotigotine transdermal patch for the treatment of neuropsychiatric symptoms in Parkinson’s disease: A meta-analysis of randomized placebo-controlled trials. J. Neurol. Sci., 2018, 393, 31-38.
[http://dx.doi.org/10.1016/j.jns.2018.08.003] [PMID: 30099246]

Rights & Permissions Print Cite
Article Metrics
95
2
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy